Back to search

Article

Discordance Between FIB-4 and BAST Fibrosis Risk Classifications in Obese Patients With MASLD: Results From the OBREDI-TR Study

2026-01-09

Abstract excerpt

<h4>Background: </h4> /Objectives: Non-invasive fibrosis scores are widely used for risk stratification in metabolic dysfunction–associated steatotic liver disease (MASLD); however, their performance in obese individuals remains controversial. The Fibrosis-4 index (FIB-4) is commonly recommended as a first-line tool, yet may underestimate fibrosis risk in severe obesity. The BAST score, which incorporates metaboli...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ce44b372-f785-5563-af0e-d0eb6de8bc35
DOI
10.20944/preprints202601.0621.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Discordance Between FIB-4 and BAST Fibrosis Risk Classifications in Obese Patients With MASLD: Results From the OBREDI-TR StudyDOI 10.20944/preprints202601.0621.v1
Select a neighboring publication to make it the new centre.